Christopher Horan, Chief Tech Operations Officer of Artiva Biotherapeutics, Inc., filed a statement of changes in beneficial ownership on November 3, 2026, disclosing a sale of common stock on November 2, 2026, related to restricted stock unit vesting.

Key Highlights

  • Reporting person: Christopher Horan, identified as Chief Tech Operations Officer of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)
  • Transaction date: November 2, 2026, with the filing submitted on November 3, 2026
  • Shares sold: 10,423 shares of common stock disposed of, coded as a sale (transaction code S)
  • Sale price: $4.1811 per share, as reported in the filing
  • Remaining ownership: 302,321 shares of common stock held directly following the transaction
  • Nature of sale: According to the filing, the shares were sold under the issuer's "sell-to-cover" policy to satisfy tax withholding obligations connected to the vesting and release of restricted stock units, and "such sales were automatic and not at the discretion of the Reporting Person"

Horan's RSU Vesting and Automatic Share Sale at Artiva Biotherapeutics

According to the filing, the sale of 10,423 shares of Artiva Biotherapeutics common stock by Christopher Horan on November 2, 2026, was not a discretionary transaction. The filing states that Artiva Biotherapeutics has adopted a "sell-to-cover" policy, under which shares are automatically sold to meet tax withholding obligations that arise when restricted stock units vest and are released to an officer or employee. The shares were disposed of at a reported price of $4.1811 each.

Artiva Biotherapeutics, Inc. is a biotherapeutics company listed on NASDAQ under the ticker ARTV. Following the reported transaction, Horan's direct beneficial ownership stood at 302,321 shares of common stock. No derivative securities transactions were reported in Table II of the filing. The filing was signed by Jennifer Bush as Attorney-in-Fact on behalf of the reporting person and was submitted as an individual, single-person filing.

What Was Disclosed

The filing disclosed that Christopher Horan, Chief Tech Operations Officer of Artiva Biotherapeutics, sold 10,423 shares of common stock on November 2, 2026, at $4.1811 per share, automatically, to cover tax obligations tied to RSU vesting, leaving him with 302,321 shares directly owned.